v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Revenue $ 41,630 $ 69,025 $ 135,877 $ 202,627
Cost of revenue 35,975 36,791 114,729 113,708
Gross Profit 5,655 32,234 21,148 88,919
Operating expenses:        
Selling, general and administrative 35,396 39,087 113,535 120,528
Research and development 3,844 4,704 13,614 14,660
Change in estimated fair value of contingent consideration 60 (178) 200 (1,373)
Goodwill impairment 0 154,239 42,884 154,239
Restructuring 7,386 (4) 7,386 (1,220)
Total operating expenses 46,686 197,848 177,619 286,834
Loss from operations (41,031) (165,614) (156,471) (197,915)
Other income (expense):        
Interest expense (6,844) (13,634) (20,437) (36,437)
Interest income 2,797 7,071 9,052 21,367
Change in payable to related parties pursuant to the Tax Receivable Agreement 0 (39) 0 (39)
Other (expense) income (71) 72 (4,109) (2,384)
Loss before income taxes (45,149) (172,144) (171,965) (215,408)
Income tax (benefit) expense (92) 311 (4,218) (1,853)
Net loss (45,057) (172,455) (167,747) (213,555)
Net loss attributable to non-controlling interests (19,501) (75,381) (72,655) (94,614)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (25,556) $ (97,074) $ (95,092) $ (118,941)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) $ (0.18) $ (0.68) $ (0.66) $ (0.87)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) $ (0.18) $ (0.68) $ (0.66) $ (0.87)
Weighted average number of Class A common shares outstanding, basic (in shares) 144,683 141,555 144,119 136,595
Weighted average number of Class A common shares outstanding, diluted (in shares) 144,683 141,555 144,119 136,595

Source